After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?

SVR rates in recent DAA combination trials are really impressive.  Hardly a month goes by without yet another trial showing excellent efficacy in populations so far considered ‘difficult to treat’, like cirrhotics or post-liver transplant patients on immunosuppressive therapies.  This Continue reading After Harvoni: What’s Still Left to Improve (Besides the Price Tag)?

2014: The Year That Changed The Landscape of HCV Therapy

It was déjà vu all over again, albeit compressed in time: when the race started to replace PegIFN+RBV for the treatment of HCV infection, the learnings from HIV drug development and the lessons with HAART provided an excellent template for quick Continue reading 2014: The Year That Changed The Landscape of HCV Therapy